Advertisement

Topics

Gilead CEO Daniel O'Day challenged over patents on PrEP drug Truvada

05:42 EDT 17 May 2019 | Pharmafile

US Representative Alexandria Ocasio-Cortez tore into Gilead CEO Daniel O’Day on Thursday, over the firm’s nearly $2,000 price tag on PrEP drug, Truvada, in the United States. Sold at a list price of $1,780 in the US, the drug costs just $8 in Australia.

read more

Original Article: Gilead CEO Daniel O'Day challenged over patents on PrEP drug Truvada

NEXT ARTICLE

More From BioPortfolio on "Gilead CEO Daniel O'Day challenged over patents on PrEP drug Truvada"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...